PMID-38440786 – Mazdutide Weight Loss Systematic Review Meta-Analysis
Chen Y, Zhang J, Wang M, et al. Efficacy and safety of mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2024;15:1341516.
Quick Reference
| Property | Value |
|---|---|
| PMID | 38440786 |
| DOI | 10.3389/fendo.2024.1341516 |
| Year | 2024 |
| Journal | Frontiers in Endocrinology |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | Pooled analysis of RCTs; diabetic and non-diabetic patients |
| Peptide(s) Studied | Mazdutide |
Key Findings
- Meta-analysis confirmed significant body weight reduction with mazdutide across all dose levels compared to placebo
- Efficacy demonstrated in both diabetic (T2D) and non-diabetic populations
- Dose-dependent weight loss confirmed across pooled studies
- Mazdutide showed significant improvements in HbA1c in diabetic subgroups
- GI adverse events (nausea, diarrhea, vomiting) were the most common, consistent across trials
- No unexpected safety signals identified in the pooled analysis
Study Design
Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials evaluating mazdutide in adults with overweight/obesity or T2D. Risk of bias assessed using Cochrane RoB 2 tool. Random-effects model used for pooled analyses. Subgroup analyses performed by diabetic status and dose level.
Limitations
- Limited to early-phase trials (Phase 1b and Phase 2 data available at time of analysis)
- All included trials conducted in Chinese populations
- Heterogeneity in dose-escalation protocols across trials
- Short follow-up durations in source trials
Clinical Relevance
This meta-analysis provides the first pooled evidence synthesis for mazdutide, confirming a consistent dose-response for weight loss and establishing its dual efficacy in both metabolic populations. The findings support the GLP-1/glucagon dual agonist mechanism as a viable therapeutic approach and provide context for interpreting the subsequent Phase 3 GLORY-1 NEJM data.
Related
#research #systematic-review #meta-analysis #mazdutide #evidence-level-I #metabolic